AN OPEN-LABEL, ASCENDING-DOSE, FIRST-INHUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF INTRAVENOUS INFUSIONS OF ATB200 ALONE AND ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH POMPE DISEASE
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Amicus Therapeutics Corporation
Start Date
April 1, 2016
End Date
September 30, 2017
Administered By
Pediatrics, Medical Genetics
Awarded By
Amicus Therapeutics Corporation
Start Date
April 1, 2016
End Date
September 30, 2017